Dr Reddys Laboratories (RDY) Equity Average (2014 - 2020)

Dr Reddys Laboratories' Equity Average history runs 7 years deep, the most recent figure standing at $2.3 billion for Q4 2020.

• In Q4 2020, Equity Average rose 8.1% year-over-year to $2.3 billion; the TTM figure through Dec 2020 stood at $2.3 billion (up 8.1% YoY), while the FY2026 annual figure was $4.0 billion, up 8.62% from the prior year.
• Equity Average was $2.3 billion for Q4 2020 at Dr Reddys Laboratories, up from $2.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $2.3 billion in Q4 2020 to a low of $1759.3 in Q4 2016.
• Historically, Equity Average has averaged $1.2 billion across 5 years, with a median of $923.5 million in 2018.
• The sharpest annual moves came in 2016 and 2017: Equity Average slumped 100.0% in 2016, then gained 9.34% in 2017.
• A 5-year view of Equity Average shows it stood at $1759.3 in 2016, then grew by 9.34% to $1923.5 in 2017, then jumped by 97530443.28% to $1.9 billion in 2018, then gained by 13.04% to $2.1 billion in 2019, then grew by 8.1% to $2.3 billion in 2020.
• The last three Equity Average figures came in at $2.3 billion (Q4 2020), $2.1 billion (Q4 2019), and $1.9 billion (Q2 2018), per Business Quant data.